JAMA Article About CMCR

The JAMA article on CMCR showed how important it is to obtain alternative sources of funding for medical marijuana research, since Center Co-director Andrew Mattison makes it clear that the ultimate goal is not FDA approval of marijuana but the development of "new molecules that interact with the body’s built-in cannabinoid receptors." Even Stage #2, which is the development by CMCR of non-smoking delivery systems, was described in the article as focusing primarily on products like the GW Pharmaceutical mucosal spray, which requires a marijuana extract, rather than the vaporizer, which can be used with the marijuana plant itself.